Lipitor

Ranbaxy Laboratories said its US unit would pay a record $500 million to settle charges of non-compliance with drug manufacturing quality norms and related falsification of data in filings made to the US Food and Drug Administration. Photo: Ramesh Pathania/Mint <br /> (Ramesh Pathania/Mint )
<br />Atorvastatin calcium tablets. Photo: Bloomberg<br />